InvestorsHub Logo
Followers 7
Posts 354
Boards Moderated 0
Alias Born 08/12/2019

Re: None

Friday, 08/07/2020 9:59:19 AM

Friday, August 07, 2020 9:59:19 AM

Post# of 8172
Cellectar can beat that ! Belantamab just approved for R/R MM with 4 prior lines of therapy including immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody, with ORR/PFS which I believe CLR-131 will match and with a much better AE profile.
Top sales estimate 2026 $1,5B based on current indications/trials, but a lot of new indications could be added down the line for Belantamab.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLRB News